Pharmacokinetics of mesalazine pellets in children with inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 10, Issue 5, 2004, Pages 626-631

  Wiersma, Heleen ^a,b   Escher, Johanna C ^c   Dilger, Karin ^d   Trenk, Dietmar ^e   Benninga, Marc A ^a   van Boxtel, Chris J ^a   Taminiau, Jan ^f  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b EMMA CHILDREN S HOSPITAL   (Netherlands)

^c SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^d Dr Falk Pharma GmbH   (Germany)

^e UNIVERSITY HEART CENTER FREIBURG BAD KROZINGEN   (Germany)

^f NONE

Author keywords

Children; Inflammatory bowel disease; Mesalazine; Pharmacokinetics; S ASA

Indexed keywords

5 ACETAMIDOSALICYLIC ACID; AZATHIOPRINE; CORTICOSTEROID DERIVATIVE; MESALAZINE; SALAZOSULFAPYRIDINE;

ADOLESCENT; AREA UNDER THE CURVE; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION COEFFICIENT; CROHN DISEASE; DATA ANALYSIS; DIZZINESS; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG EXPOSURE; DRUG FORMULATION; DRUG HALF LIFE; DRUG PELLET; DRUG URINE LEVEL; ENTERITIS; FEMALE; GEOMETRY; HUMAN; HYPOTENSION; MALE; PRIORITY JOURNAL; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; ULCERATIVE COLITIS;

ADMINISTRATION, ORAL; ADOLESCENT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AREA UNDER CURVE; CHEMISTRY, PHARMACEUTICAL; CHILD; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MESALAMINE;

EID: 4644356274     PISSN: 10780998     EISSN: None     Source Type: Journal    
DOI: 10.1097/00054725-200409000-00019     Document Type: Article

References (24)

1. Sutherland LR, May GR, Shaffer EA. Sulfasalazine revisited: a metaanalysis of 5-aminosalicylic acid in the treatment of ulcerative colitis. Ann Intern Med. 1993;118:540-549.
2. Schroeder KW. Role of mesalazine in acute and long-term treatment of ulcerative colitis and its complications. Scand J Gastroenterol Suppl. 2002;235:42-47.
3. Rasmussen SN, Lauritsen K, Tage-Jensen U, et al. 5-Aminosalicylic acid in the treatment of Crohn's disease. A 16-week double-blind, placebo-controlled, multicentre study with Pentasa. Scand J Gastroenterol. 1987; 22:877-883.
4. Singleton J. Second trial of mesalamine therapy in the treatment of active Crohn's disease. Gastroenterology. 1994;107:632-633.
5. Sutherland LR, Martin F, Bailey RJ, et al. A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group. Gastroenterology. 1997;112:1069-1077.
6. Griffiths A, Koletzko S, Sylvester F, et al. Slow-release 5-ammosalicylic acid therapy in children with small intestinal Crohn's disease. J Pediatr Gastroenterol Nutr. 1993;17:186-192.
7. Ferry GD, Kirschner BS, Grand RJ, et al. Olsalazine versus sulfasalazine in mild to moderate childhood ulcerative colitis: results of the Pediatric Gastroenterology Collaborative Research Group Clinical Trial. J Pediatr Gastroenterol Nutr. 1993;17:32-38.
8. D'Agata ID, Vanounou T, Seidman E. Mesalamine in pediatric inflammatory bowel disease: a 10-year experience. Inflamm Bowel Dis. 1996;2: 229-235.
9. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317:1625-1629.
10. Sutherland LR, Robinson M, Onstad G, et al. A double-blind, placebo-controlled, multicenter study of the efficacy and safety of 5-aminosalicylic tablets in the treatment of ulcerative colitis. Can J Gastroenterol. 1990;4:463-467.
11. Allgayer H, Ahnfelt NO, Kruis W, et al. Colonic N-acetylation of 5-aminosalicylic acid in inflammatory bowel disease. Gastroenterology. 1989; 97:38-41.
12. Klotz U. The role of aminosalicylates at the beginning of the new millennium in the treatment of chronic inflammatory bowel disease. Eur J Clin Pharmacol. 2000;56:353-362.
13. Brunner M, Greinwald R, Kletter K, et al. Gastrointestinal transit and release of 5-aminosalicylic acid from 153Sm-labelled mesalazine pellets vs. tablets in male healthy volunteers. Aliment Pharmacol Ther. 2003;17: 1163-1169.
14. Kruis W, Bar-Meir S, Feher J, et al. The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine. Clin Gastroenterol Hepatol. 2003;1:36-43.
15. Marakovski YK, Fixa J, Holoman J, et al. Mesalazine pellets for active ulcerative colitis: randomized, double-blind, multicentre, standard-controlled trial. Gut. 2001;49(suppl III):A1487.
16. Tolia V, Massoud N, Klotz U. Oral 5-aminosalicyclic acid in children with colonic chronic inflammatory bowel disease: clinical and pharmacokinetic experience..J Pediatr Gastroenterol Nutr. 1989;8:333-338.
17. Christensen LA, Fallingborg J, Jacobsen BA, et al. Bioavailability of 5-ammosalicyclic acid from slow release 5-aminosalicyclic acid drug and sulfasalazine in normal children. Dig Dis Sci. 1993;38:1831-1836.
18. Klotz U. 5-aminosalicylic acid and chronic inflammatory bowel diseases in children. Klin Padiatr. 1995;207:285-287.
19. Büller HA, Maas SM. Consensus inflammatory intestinal diseases in children: ulcerative colitis and Crohn disease. Work Group Academic Medical Centre. Amsterdam. Ned Tijdschr Geneeskd. 1996;140:544-550.
20. Fischer C, Maier K, Klotz U. Simplified high-performance liquid chromatographic method for 5-amino salicylic acid in plasma and urine. J Chromatogr. 1981;225:498-503.
21. Brendel E, Meineke I, Witsch D, et al. Simultaneous determination of 5-aminosalicylic acid and 5-acetylaminosalicylic acid by high-performance liquid chromatography. J Chromatogr. 1987;385:299-304.
22. Gibaldi M, Perrier D. Pharmacokinetics. New York: Marcel Dekker Inc., 1975.
23. Sandborn WJ, Hanauer SB. Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. Aliment Pharmacol Ther. 2003;17: 29-42.
24. Rowland M, Tozer T. Concepts and applications. In: Clinical pharmacokinetics. 3rd ed. Baltimore: Williams & Wilkins; 1995.